The DMXL1 Knockout A2780 Polyclonal Cells consist of a heterogeneous population of human A2780 ovarian carcinoma cells subjected to CRISPR/Cas9-mediated disruption of the DMXL1 gene, yielding a polyclonal knockout model. This product is supplied as a mixed pool of edited cells, enabling loss-of-function studies without clonal isolation.
The A2780 cell line was derived from an ovarian endometrioid adenocarcinoma and serves as a well-established model for human ovarian tumorigenesis. These cells retain epithelial characteristics and are widely used to investigate oncogenic signaling, drug sensitivity, and metabolic reprogramming in ovarian cancer. The host cell background provides a relevant context for exploring gene functions linked to tumor progression and therapeutic resistance.
DMXL1 encodes a scaffold protein critical for the assembly and stability of the vacuolar-type H+-ATPase (V-ATPase) complex, a multi-subunit proton pump that acidifies endolysosomal compartments. By interacting with V-ATPase subunits such as ATP6V1 and RAB GTPases, DMXL1 regulates endosomal trafficking and lysosomal acidification. This function positions DMXL1 upstream of the Ragulator?CRag GTPase module, which transduces lysosomal amino acid signals to activate mTORC1. Consequently, DMXL1 influences mTORC1-mediated phosphorylation of downstream effectors including S6 kinase (S6K) and ribosomal protein S6, while also modulating transcription factor EB (TFEB)?Cdriven autophagy and lysosomal biogenesis. Nutrient availability, cellular energy status, and feedback from mTORC1 activity further impinge on DMXL1-dependent processes, creating a regulatory node that couples metabolic cues to growth and homeostasis.
In the context of A2780 ovarian carcinoma cells, disruption of DMXL1 is expected to perturb endolysosomal acidification and mTORC1 signaling, leading to altered metabolic adaptation and autophagy. Given that ovarian cancers often exhibit dysregulated mTORC1 activity and lysosomal function, this polyclonal knockout model provides a powerful tool for dissecting how DMXL1-mediated V-ATPase regulation impacts tumor cell proliferation, survival, and chemoresistance. Moreover, it facilitates the study of cross-talk between endocytic trafficking and oncogenic pathways in a disease-relevant cellular environment.
Researchers can employ this model for diverse applications, including quantitative western blot analysis of mTORC1 targets (phospho-S6K, phospho-S6) to assess signaling flux, LysoTracker staining to monitor lysosomal acidification, and LC3-II turnover assays to measure autophagic flux. Immunofluorescence detection of endosomal and lysosomal markers permits spatial resolution of trafficking defects, while cell viability and clonogenic survival assays reveal functional consequences of DMXL1 loss under nutrient stress or drug treatment. Transcriptomic profiling via RNA-seq enables unbiased identification of DMXL1-dependent gene networks in ovarian cancer cells. These tools collectively support investigations into metabolic reprogramming, autophagy regulation, and therapeutic vulnerability. For additional technical details, please contact Ascent Research.
